Cephalon, Inc.
Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
-
That growth was steady, as revenue grew every year and earnings only decreased in 2008, due to the costs of acquiring Barr Pharmaceuticals Inc. Acquisitions were another major aspect of Yanai's reign as CEO. Barr Pharmaceuticals was one of the three... Full Article at Seeking Alpha
-
Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
PR Newswire
Cephalon paid Ambit an upfront fee of $15.5 million as partial consideration for access to Ambit's kinase profiling technology and licenses contributed by Ambit to the drug discovery part of the collaboration. Ambit may be entitled to receive greater... Full Article at PR Newswire
-
Cephalon also provided diversification into new pain and oncology treatments, while strengthening Teva’s branded business ahead of impending generic erosion in the key Copaxone Multiple Sclerosis drug
SOURCE: Forbes -
If ever there was a safe recreational drug, modafinil seemed to be it. The greatest little pick-me-up since the cup of joe or so its enthusiasts said the antinarcolepsy medication has helped recreational and casual users stay peppy without the... Full Article at Time Magazine
-
Even as UCB’s Keppra Captures the Largest Patient Share, Followed by GSK’s Lamictal, Strong Company Support and Positive Efficacy Performance Drive Uptake of UCB’s Vimpat in the Epilepsy Market, According to a Recent BioTrends Report
Business Wire
The report also finds that, although the 101 surveyed U.S. neurologists prescribe generic formulations of both first- and second-generation AEDs to their epilepsy patients the majority of the time, they typically stay with the branded formulations of... Full Article at Business Wire
-
Zacks Reiterates “Neutral” Rating on Teva Pharmaceutical Industries Ltd (TEVA)
American Banking and Market NewsRevenues increased 25% to $5.1 billion, missing the Zacks Consensus Estimate of $5.6 billion. We expect generic sales to continue improving in 2012 given the exclusive launch of generic Zyprexa. Longer-term, Teva’s acquisition of Cephalon should help... Full Article at American Banking and Market News
-
-
Together we turned Teva into a highly diversified global pharmaceutical company, with an expanded geographical footprint and additional lines of business." Referring to the financial report, the departing chief executive said the company began 2012 on... Full Article at Haaretz
-
Research & Development expense increased to $292 million from $239 million in the year-ago period. The inclusion of Cephalon was the main reason for the increase. Meanwhile, Selling and Marketing (S&M) expenditure increased to $916 million from $825... Full Article at Zacks Investment Research
-
In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Fed. Cir. 2012)
Patent Docs
The case involved ANDA litigation under 35 U.S.C. § 271(e)(2) relating to generic versions of "modified-release dosage forms" of cyclobenzaprine hydrochloride, a muscle relaxing drug marketed as Amrix by Cephalon (owner of exclusive patent licensee... Full Article at Patent Docs
About this topic
Wikipedia
There are no results for this module. Edit this module to change the search term used to query Wikipedia
Search Independent.ie topics
Related topics
Related videos
Related Conversations
There are no results for this module. Edit the module to change the search term used to query Twitter.
We found no conversations related to Cephalon, Inc.
Newsmap
See the geographical connection between Cephalon, Inc. and different parts of the world. Mouse over the map pins to explore connections.
There are no results for this module.
Sponsored Features
Highlights
Independentwoman.ie
Independent Woman
A fresh, fun site featuring celeb gossip, fashion, beauty, love & sex, and health & fitness.
- Independent Channels:
-
RSSLearn more...
-
MobileLearn more...
-
FacebookLearn more...
